SG Americas Securities
BLCM

SG Americas Securities’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

SG Americas Securities’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,859
Closed -$83K – 3704
2018
Q4 		$83K Buy
+2,859
New +$127K ﹤0.01% 2762
2017
Q1 		– Sell
-1,511
Closed -$206K – 3630
2016
Q4 		$206K Buy
1,511
+886
+142% +$157K ﹤0.01% 2327
2016
Q3 		$124K Buy
+625
New +$108K ﹤0.01% 2893

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SG Americas Securities's BLCM Position: Q1 2019 in Review

SG Americas Securities sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2019, closing a stake of 2,859 shares — an estimated $83K sold.

SG Americas Securities first reported a position in BLCM in Q3 2016 and held it in 3 quarters. The position peaked at $206K in Q4 2016. 94 funds tracked by Wall St. Rank hold BLCM as of Q1 2019.

  • SG Americas Securities reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • SG Americas Securities sold 2,859 Bellicum Pharmaceuticals, Inc. shares in Q1 2019, an estimated $83K.
  • SG Americas Securities first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • SG Americas Securities's Bellicum Pharmaceuticals, Inc. position peaked at $206K in Q4 2016.
  • 94 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2019.

Based on SG Americas Securities's 13F filing for Q1 2019, filed 29 Apr 2019.